[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2012000766A - Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina. - Google Patents

Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina.

Info

Publication number
MX2012000766A
MX2012000766A MX2012000766A MX2012000766A MX2012000766A MX 2012000766 A MX2012000766 A MX 2012000766A MX 2012000766 A MX2012000766 A MX 2012000766A MX 2012000766 A MX2012000766 A MX 2012000766A MX 2012000766 A MX2012000766 A MX 2012000766A
Authority
MX
Mexico
Prior art keywords
compound
erythropoietin production
prolyl hydroxylase
action
hydroxylase inhibitor
Prior art date
Application number
MX2012000766A
Other languages
English (en)
Spanish (es)
Inventor
Takashi Ito
Masahiro Yokota
Kazuhito Ueyama
Ikuo Mitani
Yosuke Ogoshi
Takuya Matsui
Masakazu Terashita
Dai Motoda
Takahiro Hotta
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MX2012000766A publication Critical patent/MX2012000766A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
MX2012000766A 2009-07-17 2010-07-16 Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina. MX2012000766A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009169565 2009-07-17
US27312709P 2009-07-30 2009-07-30
PCT/JP2010/062037 WO2011007856A1 (ja) 2009-07-17 2010-07-16 トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用

Publications (1)

Publication Number Publication Date
MX2012000766A true MX2012000766A (es) 2012-02-08

Family

ID=43449466

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000766A MX2012000766A (es) 2009-07-17 2010-07-16 Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina.

Country Status (29)

Country Link
US (3) US8283465B2 (ja)
EP (3) EP3594213A1 (ja)
JP (9) JP5021797B2 (ja)
KR (4) KR101850661B1 (ja)
CN (1) CN102471337B (ja)
AR (1) AR077417A1 (ja)
AU (1) AU2010271732B2 (ja)
BR (1) BR112012001157A2 (ja)
CA (1) CA2768505C (ja)
CO (1) CO6430426A2 (ja)
DK (1) DK2455381T5 (ja)
ES (1) ES2477968T3 (ja)
HK (1) HK1168346A1 (ja)
HR (1) HRP20140705T1 (ja)
IL (1) IL217541A (ja)
ME (1) ME01858B (ja)
MX (1) MX2012000766A (ja)
MY (1) MY160814A (ja)
NZ (1) NZ598242A (ja)
PE (1) PE20120629A1 (ja)
PL (1) PL2455381T3 (ja)
PT (1) PT2455381E (ja)
RS (1) RS53499B1 (ja)
RU (1) RU2538963C2 (ja)
SG (1) SG178049A1 (ja)
SI (1) SI2455381T1 (ja)
SM (1) SMT201500122B (ja)
TW (1) TWI485150B (ja)
WO (1) WO2011007856A1 (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102471337B (zh) * 2009-07-17 2014-12-10 日本烟草产业株式会社 三唑并吡啶化合物及其作为脯氨酰基羟化酶抑制剂和红细胞生成素产生诱导剂的作用
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CA2896437C (en) 2012-11-26 2021-01-19 Takaaki Abe Erythropoietin expression promoter
AP2015008502A0 (en) 2012-12-24 2015-06-30 Cadila Healthcare Ltd Novel quinolone derivatives
JP2016521747A (ja) 2013-06-13 2016-07-25 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 貧血治療のための組成物及び方法
RU2534804C1 (ru) * 2013-08-05 2014-12-10 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ, ПРОЯВЛЯЮЩИЕ СВОЙСТВА АНТАГОНИСТОВ АДЕНОЗИНОВЫХ А2А РЕЦЕПТОРОВ, И ИХ ПРИМЕНЕНИЕ
PL3052096T3 (pl) * 2013-10-03 2018-07-31 Kura Oncology Inc Inhibitory ERK i sposoby ich zastosowania
EP3190104B1 (en) 2014-09-02 2021-10-27 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
JP2018039733A (ja) * 2014-12-22 2018-03-15 株式会社富士薬品 新規複素環誘導体
GB201504565D0 (en) * 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
JP6814134B2 (ja) * 2015-05-28 2021-01-13 日本たばこ産業株式会社 糖尿病性腎症を治療又は予防する方法
CN110214139B (zh) * 2016-11-25 2022-08-23 日本烟草产业株式会社 用于生产三唑并吡啶化合物的方法
CN113004271A (zh) 2017-05-09 2021-06-22 杭州安道药业有限公司 吲哚嗪衍生物及其在医药上的应用
US10752596B2 (en) * 2017-10-04 2020-08-25 Japan Tobacco Inc. Nitrogen-containing heteroaryl compound and pharmaceutical use thereof
CN107739378A (zh) * 2017-11-14 2018-02-27 杭州安道药业有限公司 吲哚嗪衍生物及其在医药上的应用
TWI814903B (zh) * 2018-09-13 2023-09-11 日商橘生藥品工業股份有限公司 咪唑吡啶酮化合物
CN110105355B (zh) * 2019-05-24 2021-09-21 烟台大学 一种1,2,3-三唑-[1,5-a]并喹啉类化合物的制备方法
WO2021182490A1 (ja) * 2020-03-11 2021-09-16 キッセイ薬品工業株式会社 イミダゾピリジノン化合物又はその塩の結晶
JP7504822B2 (ja) 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
TW202200134A (zh) 2020-04-20 2022-01-01 美商阿克比治療有限公司 治療病毒感染、器官損傷及相關症狀之方法
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN113387948B (zh) * 2021-02-06 2022-06-10 成都诺和晟泰生物科技有限公司 一种稠环杂芳基衍生物及其药物组合物和治疗方法及用途
WO2022251563A1 (en) 2021-05-27 2022-12-01 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
CN113582843A (zh) * 2021-09-09 2021-11-02 无锡捷化医药科技有限公司 一种5-氯-2-氟-3-羟基苯甲酸乙酯的制备方法
CN116496269A (zh) * 2021-12-02 2023-07-28 苏中药业集团股份有限公司 一种脯氨酰羟化酶抑制剂及其用途
CN114031619A (zh) * 2021-12-17 2022-02-11 山东汇海医药化工有限公司 一种图卡替尼中间体的制备方法
WO2024061172A1 (zh) * 2022-09-19 2024-03-28 苏中药业集团股份有限公司 一种脯氨酰羟化酶抑制剂及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6355653B1 (en) * 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
CN1564686A (zh) * 2001-10-08 2005-01-12 弗·哈夫曼-拉罗切有限公司 8－氨基－[1,2,4]三唑并[1,5－a]吡啶－6－甲酰胺
US7544699B2 (en) 2003-08-08 2009-06-09 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
MX2007001431A (es) * 2004-08-05 2007-04-02 Hoffmann La Roche Derivados de indol, de indazol o de indolina.
FR2889383A1 (fr) * 2005-08-01 2007-02-02 France Telecom Procede et dispositif de detection pour systeme mimo, systeme mimo, programme et support d'information
TW200808793A (en) 2006-03-07 2008-02-16 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
WO2007136990A2 (en) * 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
PL3026044T3 (pl) * 2006-06-26 2019-04-30 Akebia Therapeutics Inc Inhibitory prolilo-hydroksylazy i sposoby ich użycia
WO2008006540A1 (en) 2006-07-12 2008-01-17 Syngenta Participations Ag Triazolopyridine derivatives as herbicides
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
WO2008130600A2 (en) * 2007-04-18 2008-10-30 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
US8097620B2 (en) 2007-05-04 2012-01-17 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
JP5408434B2 (ja) 2007-07-03 2014-02-05 アステラス製薬株式会社 アミド化合物
AU2008331480A1 (en) * 2007-11-30 2009-06-11 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
WO2009070644A1 (en) * 2007-11-30 2009-06-04 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009126624A1 (en) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
JP2011519858A (ja) * 2008-04-30 2011-07-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラ−ゼ阻害剤
EP2297144A1 (en) 2008-05-29 2011-03-23 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators
PL2379548T3 (pl) 2008-12-19 2016-08-31 Leo Pharma As Triazolopirydyny jako inhibitory fosfodiesterazy do leczenia chorób skórnych
CN102471337B (zh) * 2009-07-17 2014-12-10 日本烟草产业株式会社 三唑并吡啶化合物及其作为脯氨酰基羟化酶抑制剂和红细胞生成素产生诱导剂的作用

Also Published As

Publication number Publication date
EP2455381B9 (en) 2014-10-22
IL217541A (en) 2014-07-31
EP3594213A1 (en) 2020-01-15
RU2012105467A (ru) 2013-08-27
KR20120051704A (ko) 2012-05-22
US20110077267A1 (en) 2011-03-31
RS53499B1 (en) 2015-02-27
TWI485150B (zh) 2015-05-21
EP2455381A4 (en) 2012-12-12
PE20120629A1 (es) 2012-05-30
JP2024091878A (ja) 2024-07-05
SI2455381T1 (sl) 2014-08-29
KR20170018105A (ko) 2017-02-15
CA2768505A1 (en) 2011-01-20
JP2016040321A (ja) 2016-03-24
JP2015003933A (ja) 2015-01-08
SG178049A1 (en) 2012-03-29
HRP20140705T1 (hr) 2014-09-12
ES2477968T3 (es) 2014-07-18
IL217541A0 (en) 2012-02-29
JP5021797B2 (ja) 2012-09-12
CO6430426A2 (es) 2012-04-30
JP2019019144A (ja) 2019-02-07
MY160814A (en) 2017-03-31
BR112012001157A2 (pt) 2016-02-23
PT2455381E (pt) 2014-06-24
KR101850661B1 (ko) 2018-04-19
EP2455381A1 (en) 2012-05-23
PL2455381T3 (pl) 2014-10-31
ME01858B (me) 2014-12-20
JP2012144571A (ja) 2012-08-02
JP2017214404A (ja) 2017-12-07
EP2746282A1 (en) 2014-06-25
KR20230165366A (ko) 2023-12-05
AR077417A1 (es) 2011-08-24
KR20180042443A (ko) 2018-04-25
SMT201500122B (it) 2015-07-09
NZ598242A (en) 2013-09-27
AU2010271732A1 (en) 2012-03-08
JP2011037841A (ja) 2011-02-24
JP2022126843A (ja) 2022-08-30
AU2010271732B2 (en) 2016-08-25
US20160145254A1 (en) 2016-05-26
DK2455381T3 (da) 2014-07-21
KR101706803B1 (ko) 2017-02-14
EP2455381B1 (en) 2014-05-28
JP2020111612A (ja) 2020-07-27
ES2477968T9 (es) 2014-11-13
CA2768505C (en) 2018-06-12
WO2011007856A1 (ja) 2011-01-20
US8283465B2 (en) 2012-10-09
RU2538963C2 (ru) 2015-01-10
CN102471337B (zh) 2014-12-10
HK1168346A1 (en) 2012-12-28
TW201105671A (en) 2011-02-16
JP6434575B2 (ja) 2018-12-05
US20130096155A1 (en) 2013-04-18
CN102471337A (zh) 2012-05-23
DK2455381T5 (en) 2015-02-09

Similar Documents

Publication Publication Date Title
MX2012000766A (es) Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina.
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
IL203448A (en) History of azabiphenylaminobenzoic acid for use in the treatment or prevention of a pathological condition or disease susceptible to reduction by dhodh inhibition and medicinal preparations containing them
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
AU2012214029A8 (en) Rorgammat inhibitors
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
SG11201408052WA (en) IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
WO2008011131A3 (en) Amide compounds
WO2008011130A3 (en) Amide compounds
WO2008075172A3 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
MX2009012168A (es) Derivados de pirrolopiridina y su uso como inhibidores de la enzima que escinde la proteina precursora de amiloide por el sitio beta.
UA115427C2 (uk) Бензиламінові похідні як інгібітори калікреїну плазми
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
NZ600874A (en) Fluorinated derivatives of deferiprone
TN2012000092A1 (en) Therapeutic agent for mood disorders
IN2012DN01273A (ja)
MX2012006026A (es) Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
NZ596000A (en) Carboxamide compounds and their use as calpain inhibitors
WO2011050095A3 (en) Prevention and treatment of post-operative cognitive dysfunction (pocd)
WO2011159124A3 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
MA32375B1 (fr) Derives de 5-hydroxymethyl-oxazolidine-2-one pour le traitement de maladies intestinales bacteriennes

Legal Events

Date Code Title Description
FG Grant or registration